Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer
1998

Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer

Sample size: 96 publication Evidence: moderate

Author Information

Author(s): B Nakata, K Hirakawa, Y S Chung, Y Kato, Y Yamashita, A Inul, Y Arimoto, K Maeda, N Onoda, T Sawada, M Sowa

Primary Institution: Osaka City University Medical School

Hypothesis

The serum soluble interleukin-2 receptor (sIL-2R) level can serve as a prognostic indicator in gastric cancer patients.

Conclusion

Serum sIL-2R may predict the outcome of gastric cancer patients with stage III or IV disease.

Supporting Evidence

  • Stage III and IV patients had significantly higher sIL-2R levels than lower stage patients and control subjects.
  • The high sIL-2R group had a significantly worse prognosis than the low sIL-2R group.
  • Multivariate analysis demonstrated that serum sIL-2R level is an independent prognostic indicator.

Takeaway

Doctors can check a substance in the blood called sIL-2R to see how likely it is that someone with advanced stomach cancer will do well.

Methodology

Serum sIL-2R levels were measured in 96 gastric cancer patients and 100 healthy controls using enzyme-linked immunosorbent assay.

Limitations

The study excluded patients with multiple cancers or autoimmune diseases, which may limit the generalizability of the findings.

Participant Demographics

Mean age of patients was 58.2 years, with a male-to-female ratio of 67:29.

Statistical Information

P-Value

0.0002

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication